Article ; Online: Pharmacological management of gambling disorder: an update of the literature.
Expert review of neurotherapeutics
2024 Volume 24, Issue 4, Page(s) 391–407
Abstract: Introduction: Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions.: Areas ...
Abstract | Introduction: Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions. Areas covered: This narrative review explores existing pharmacological treatments for GD. The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escitalopram, and citalopram), glutamatergic agents (e.g. N-acetylcysteine (NAC), acamprosate, and memantine), mood stabilizers (e.g. topiramate, carbamazepine, lithium), and other medications (e.g. modafinil, nefazodone, olanzapine, haloperidol, tolcapone, and bupropion). Expert opinion: Due to the limitations of the studies reviewed, solid conclusions regarding the optimal choice of pharmacotherapy for individuals with GD are challenging to draw at this time. Despite some medications, such as naltrexone and nalmefene, showing promising results, efficacy has varied across studies. The review highlights current gaps/limitations, including small sample sizes, limited diversity in participant demographics, the need for exploring different gambling subtypes and treatment responses, high placebo response rates, lack of longer-term longitudinal information, limited investigation of neurobiological correlates and co-occurring disorders, and the importance of implementation research. Further research is needed to address these gaps and explore additional medications, as well as interventions like neuromodulation. |
---|---|
MeSH term(s) | Humans ; Gambling/drug therapy ; Naltrexone/therapeutic use ; Behavior, Addictive/drug therapy ; Behavior, Addictive/psychology ; Narcotic Antagonists/therapeutic use ; Selective Serotonin Reuptake Inhibitors |
Chemical Substances | Naltrexone (5S6W795CQM) ; Narcotic Antagonists ; Selective Serotonin Reuptake Inhibitors |
Language | English |
Publishing date | 2024-03-01 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 2112534-X |
ISSN | 1744-8360 ; 1473-7175 |
ISSN (online) | 1744-8360 |
ISSN | 1473-7175 |
DOI | 10.1080/14737175.2024.2316833 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6155: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.